Literature DB >> 26658933

Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our Preconceptions.

Mark Crowther1,2,3, Wendy Lim4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26658933      PMCID： PMC4720638          DOI： 10.1007/s11606-015-3525-x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  5 in total

1.  Dalteparin versus unfractionated heparin in critically ill patients.

Authors:  Deborah Cook; Maureen Meade; Gordon Guyatt; Stephen Walter; Diane Heels-Ansdell; Theodore E Warkentin; Nicole Zytaruk; Mark Crowther; William Geerts; D Jamie Cooper; Shirley Vallance; Ismael Qushmaq; Marcelo Rocha; Otavio Berwanger; Nicholas E Vlahakis
Journal:  N Engl J Med       Date:  2011-03-22       Impact factor: 91.245

2.  Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Authors:  Wendy Lim; Francesco Dentali; John W Eikelboom; Mark A Crowther
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

3.  Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.

Authors:  Doyun Park; William Southern; Manuela Calvo; Margarita Kushnir; Clemencia Solorzano; Mark Sinnet; Henny H Billett
Journal:  J Gen Intern Med       Date:  2015-07-25       Impact factor: 5.128

4.  Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.

Authors:  James Douketis; Deborah Cook; Maureen Meade; Gordon Guyatt; William Geerts; Yoanna Skrobik; Martin Albert; John Granton; Paul Hébert; Guiseppe Pagliarello; John Marshall; Robert Fowler; Andreas Freitag; Christian Rabbat; David Anderson; Nicole Zytaruk; Diane Heels-Ansdell; Mark Crowther
Journal:  Arch Intern Med       Date:  2008-09-08

5.  A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.

Authors:  Seth Woodruff; Guillaume Feugère; Paula Abreu; Joseph Heissler; Marcia T Ruiz; Frank Jen
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300
  5 in total
  1 in total

Review 1.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.

Authors:  Zhenguo Zhai; Chenghong Li; Yaolong Chen; Grigorios Gerotziafas; Zhenlu Zhang; Jun Wan; Peng Liu; Ismaïl Elalamy; Chen Wang
Journal:  Thromb Haemost       Date:  2020-04-21       Impact factor: 5.249
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.